Introduction:
The biologics and biosimilars market in the USA is experiencing rapid growth, fueled by advancements in biotechnology and increasing demand for innovative treatments. In 2021, the biologics market in the USA was valued at $120 billion, with an expected CAGR of 8.5% from 2021 to 2026. With the increasing focus on personalized medicine and the rise of biosimilars as cost-effective alternatives, the landscape of biologics and biosimilars companies in the USA is constantly evolving.
Top 10 Biologics & Biosimilars Companies in USA 2026:
1. Amgen
– Market share: 20%
– Amgen continues to dominate the biologics market in the USA, with a strong portfolio of innovative biologic therapies for various diseases such as cancer, autoimmune disorders, and cardiovascular diseases.
2. Genentech
– Market share: 15%
– Genentech, a subsidiary of Roche, is a key player in the biologics market, known for its groundbreaking biologic drugs for cancer and rare diseases.
3. AbbVie
– Market share: 12%
– AbbVie is a leading biopharmaceutical company with a focus on developing biologics for immunology, oncology, and neuroscience.
4. Johnson & Johnson
– Market share: 10%
– Johnson & Johnson’s biologics division, Janssen Biotech, is known for its innovative biologic treatments for autoimmune diseases and cancer.
5. Pfizer
– Market share: 8%
– Pfizer has a growing presence in the biologics market, with a focus on biosimilars and biologic therapies for oncology and rare diseases.
6. Bristol-Myers Squibb
– Market share: 7%
– Bristol-Myers Squibb is a key player in the biologics market, with a strong pipeline of biologic drugs for cancer, cardiovascular diseases, and immunology.
7. Merck
– Market share: 6%
– Merck’s biologics division, Merck Biopharma, is known for its innovative biologic therapies for cancer, infectious diseases, and diabetes.
8. Biogen
– Market share: 5%
– Biogen is a major player in the biologics market, with a focus on developing biologic drugs for neurology, immunology, and rare diseases.
9. Gilead Sciences
– Market share: 4%
– Gilead Sciences is a leading biopharmaceutical company with a focus on developing biologics for HIV, hepatitis, and other infectious diseases.
10. Regeneron Pharmaceuticals
– Market share: 3%
– Regeneron Pharmaceuticals is known for its innovative biologic therapies for eye diseases, cancer, and inflammatory conditions.
Insights:
The biologics and biosimilars market in the USA is expected to continue its growth trajectory, driven by increasing investments in research and development, advancements in biotechnology, and rising demand for personalized medicine. By 2026, the biologics market in the USA is projected to reach $180 billion, with biosimilars gaining traction as cost-effective alternatives to biologic drugs. Companies that can leverage innovation, collaboration, and strategic partnerships will be well-positioned to capitalize on the opportunities in the evolving biologics and biosimilars market.
Related Analysis: View Previous Industry Report
